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Abstract Background Hirudin is an anti-coagulative
product of the salivary glands of the medicinal leech
Hirudo medicinalis. It is a powerful and speciﬁc thrombin
inhibitor. Peptides containing the RGD motif competitively
inhibit the binding of ﬁbrinogen to GP IIb/IIIa on the
platelets, thus inhibiting platelet aggregation. Results We
have constructed a recombinant RGD-hirudin (r-RGD-
hirudin) by fusing the tripeptide RGD sequence to the
native hirudin (wt-hirudin). The r-RGD-hirudin was
expressed at high levels in Pichia pastoris, and was puri-
ﬁed to *97% homogeneity. The speciﬁc anti-thrombin
activity of puriﬁed r-RGD-hirudin is 12,000 ATU/mg,
which is equivalent to wt-hirudin, but only r-RGD-hirudin
can inhibit platelet aggregation. The biological effects of
r-RGD-hirudin on Thrombin Time (TT), Prothrombin
Time (PT), Activated Partial Thromboplastin Time
(APTT), Bleeding Time (BT), maximum platelet aggre-
gation (PAGm) induced by ADP were studied in rabbit
model and compared with that of wt-hirudin. The rabbits
were infused r-RGD-hirudin had prolonged TT, PT, and
aPTT which were similar to that of wt-hirudin; but only
r-RGD-hirudin was capable of inhibiting PAGm. Histopa-
thological analyses showed that r-RGD-hirudin was two to
three times more effective than wt-hirudin in preventing
thrombosis. Conclusions r-RGD-hirudin can potentially be
used as a novel anti-coagulant for the prevention of
thrombosis after carotid artery anastomosis or in other
thrombotic events.
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Introduction
Hirudin is an anti-coagulative product of the salivary
glands of the medicinal leech Hirudo medicinalis.I ti sa
powerful and speciﬁc thrombin inhibitor. Unlike heparin,
which acts by binding to anti-thrombin III, hirudin binds
directly to thrombin, and inhibits ﬁbrin-bound as well as
ﬂuid-phase thrombin. It also inhibits ﬁbrinogen clotting
and thrombin-catalysed haemostatic reactions [1].
The native hirudin (wt-hirudin) is a single-chain, car-
bohydrate-free polypeptide containing 65–66 amino acids
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DOI 10.1007/s11239-008-0251-9with a molecular weight of 7,000 Da. Wt-hirudin has a
trisulﬁde-linked core structure, forming a compact NH2-
terminal domain and a long COOH-terminal extended
domain. The crystal structure of hirudin–thrombin complex
revealed abundant polar and apolar interactions between
these two molecules, which may account for the tight
afﬁnity and speciﬁcity of hirudin binding [2].
Adhesion of platelets to vessel walls, their activation,
and aggregation are key events in blood coagulation. On
activated platelets, the glycoprotein IIb/IIIa (GP IIb/IIIa)
functions as a receptor for ﬁbrinogen to mediate platelet
aggregation and cross-linking. The capability of GP IIb/IIIa
to bind to ﬁbrinogen and other adhesive proteins is due to
its ability to recognize the Arg–Gly–Asp (RGD) motif
within their sequences. Peptides containing the RGD motif
or RGD itself competitively inhibit the binding of ﬁbrin-
ogen to GP IIb/IIIa on the platelets, thus inhibiting platelet
aggregation [3]. Adelman et al. [4] showed that peptides
with RGD efﬁciently prevent platelet aggregation induced
by ADP.
In the present study, we engineered a novel bi-functional
hirudin molecule, r-RGD-hirudin, by fusing an RGD tri-
peptide to the wt-hirudin. We reasoned that this r-RGD-
hirudin should be able to inhibit both thrombin and platelet
aggregation. We then studied r-RGD-hirudin as a novel
anti-coagulant with improved efﬁcacy and safety (com-
paring it with heparin or wt-hirudin) because of its unique
bi-functional features.
Results
Analysis of r-RGD-hirudin-pPIC9K expression plasmid
The designed clone was constructed, identiﬁed by restric-
tion map, and was subsequently conﬁrmed by sequencing
analysis.
Integration of r-RGD-hirudin encoding gene into Pichia
pastoris chromosome
As 700 bp and 2.2 kb bands of PCR products were
observed in 1.0% agarose gel electrophoresis, we con-
ﬁrmed that the expression plasmid was integrated into the
Pichia pastoris chromosome and that phenotype was Mut
?.
Expression of r-RGD-hirudin in Pichia pastoris
Mut
? transformants were grown in shake ﬂask and
screened for those that secreted r-RGD-hirudin to the
growth medium with high level. After 2 days of methanol
induction, the anti-thrombin activity of expression product
in the culture was up to 3,500 ATU/ml as determined by
ﬁbrinogen solidiﬁcation assay. SDS-PAGE showed that the
expression level of r-RGD-hirudin was as high as 85% of
the culture (Fig. 1). Analysis by LC/MS indicated that the
molecular weight of r-RGD-hirudin was about 7 kDa
(Fig. 2).
Scale up production of r-RGD-hirudin and its in vitro
anti-thrombin activity assay
After 2 days of fermentation, the media were collected by
centrifugation, and then concentrated by ultra-ﬁltration.
The concentrated media were subjected to gel ﬁltration and
anion exchange chromatography. The purity of r-RGD-
hirudin was up to 97% and the speciﬁc activity was over
12,000 ATU/mg. About 1.5 g of puriﬁed r-RGD-hirudin
was generated from 1 l culture.
Platelet aggregation assay
r-RGD-hirudin was shown to inhibit ADP induced platelet
aggregation in a dose-dependent manner, whereas wt-
hirudin did not appear to harbor the same activity (Fig. 3).
The binding of r-RGD-hirudin to platelet was quantiﬁed
by Average Fluorescence Intensity which was rectiﬁed by
subtracting values of non-speciﬁc binding and blank
(Table 1).
Pharmacodynamics study: in the rabbit model to study
the anti-thrombotic effects of r-RGD-hirudin
Pathological analysis indicated that the anti-thrombotic
effect of r-RGD-hirudin was dose-dependent. The effective
dose was only 1/2–1/3 of wt-hirudin (Table 2, Fig. 4). The
result of DSA showed that within 3 days of surgery
(Fig. 5), in the control group, or groups treated with
abciximab or a low dose of r-RGD-hirudin, there were
thrombosis in the blood vessels undergone surgery; while
Fig. 1 SDS-PAGE pattern of r-RGD-hirudin in the culture during
methanol induction. M: protein marker. I0: before methanol induction.
I1–7: seven samples with methanol induction for 2 days. S: wt-hirudin.
It was same with wt-hirudin that the expression level of r-RGD-
hirudin was more than 85%. r-RGD-hirudin was excreted into
supernatant of culture
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recirculation was complete in the blood vessels. Haema-
tological assay showed that TT, PT, and APTT were
prolonged after infusion of r-RGD-hirudin or wt-hirudin,
and r-RGD-hirudin was capable of inhibiting platelet
aggregation (Fig. 6).
Bleeding time
Compared with NS control, bleeding time was prolonged
after infusion of r-RGD-hirudin for 1.5 h (especially at
1.0 mg/kg), and wt-hirudin (1.0 mg/kg) for 1.0 h
(Table 3).
Discussion
Thrombin is a central regulator in the coagulation cascade
and inﬂammation process [5]. In the process of venous
thrombogenesis, several thrombin inhibitors with pharma-
cological proﬁles different from the conventional anti-
coagulant heparin are currently in clinical use for throm-
boembolic indications. One of them is the direct thrombin
inhibitor recombinant hirudin [6]. In the artery, platelet
aggregation may play a crucial role in thrombosis. Platelet
aggregation inhibitors, which interfere in the interac-
tions between ﬁbrinogen and its receptor, the GP IIb/IIIa
complex, show extreme structural diversity but they share
the common functional feature of (RGD) tripeptide
segment [7].
We have constructed a fusion gene encoding a novel
anti-coagulant, r-RGD-hirudin, and expressed it at high
levels in Pichia pastoris. The r-RGD-hirudin is a
Fig. 2 LC/MS analysis of
puriﬁed r-RGD-hirudin. The
molecular weight of r-RGD-
hirudin was about 7,031 Da
which is consistent with
theoretics
Fig. 3 The effects of r-RGD-hirudin and wt-hirudin on rabbit
platelet-aggregation induced by ADP. (j) r-RGD-hirudin inhibited
platelet aggregation induced by ADP in a dose-dependent manner;
(r) wt-hirudin was not capable of inhibiting platelet aggregation
induced by ADP; r-RGD-hirudin 0.14 lmol/l could inhibit the
platelet aggregation, and its inhibitory effect on the platelet aggre-
gation was dose-response, however, wt-hirudin had no effect on the
platelet aggregation which was induced by ADP
Table 1 Average ﬂuorescence intensity
Final concentration of r-RGD-hirudin
(lmol/l)
Fluorescence intensity
(Means ± SD)
0.02 6.27 ± 0.13
0.04 13.72 ± 1.03
0.09 16.99 ± 1.21
0.18 27.67 ± 1.57
0.36 37.11 ± 1.90
0.88 56.78 ± 2.35
1.78 57.70 ± 2.54
IC50 was 0.3 lmol/l which was calculated by linear correlation
(Y = 12.25 ? 54.18X, R = 0.96, X means ﬁnal concentration of
r-RGD-hirudin and Y means ﬂuorescence intensity)
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123bi-functional molecule containing domain for speciﬁc
thrombin inhibition and RGD sequence for blocking
platelet aggregation. In animal studies, we demonstrated
that r-RGD-hirudin was able to prevent thrombogenesis
more effectively than both heparin and wt-hirudin.
In r-RGD-hirudin, the RGD tripeptide was fused into the
loop region within the wt-hirudin molecule. The structure
and function of wt-hirudin were not changed, and the fusion
RGDtripeptidewasabletobindtoGPIIb/IIIaofplateletand
inhibit platelet aggregation at the mean time. Fibrinogen
solidiﬁcation assay showed that r-RGD-hirudin strongly
inhibited thrombin, and the speciﬁc anti-thrombin activity
was similar to that of wt-hirudin. Molecular docking of
r-RGD-hirudin on thrombin indicated that RGD tripeptide
was always at the surface of the complex, which means the
RGD tripeptide could bind to GP IIb/IIIa receptor freely.
This is consistent with the ﬁnding that r-RGD-hirudin could
inhibit platelet aggregation in vitro and in vivo assay.
Microsurgery is currently an established technique being
used in various surgical specialties such as plastic surgery,
neurosurgery, and transplantation surgery [8]. Microvascular
freetissuetransfersatpresentresultsinaveryhighfailurerate
due primarily to thrombosis of the blood vessels at the anas-
tomoticsite.Previousresearchintheﬁeldhasshownthatanti-
coagulants such as heparin can reduce the rate of thrombosis.
Although heparin is being used as anti-coagulants in micro-
surgery, bleeding problems have been a troublesome side
effect. Recent studies have shown that wt-hirudin may be
useful in eliminating unwanted bleeding episodes in the face
of effective anti-coagulation [9]. The development of new
anti-coagulantshasbeenpursuedwiththeaimofﬁndingmore
effective, safer and/or more convenient therapies. So, this
model was suitable for pharmacodynamics studies which
focused on anti-coagulant research.
Our r-RGD-hirudin contains both the native hirudin
sequence and an additional RGD sequence. It is capable of
Table 2 Recirculation of rabbit carotid artery on anastomosis area (*P\0.05)
Thrombosis Partial recirculation Completely recirculation
NS control (n = 7) 4/7 3/7 0/7
Abciximab 0.2 mg/kg (n = 7) 2/7 3/7 2/7
wt-hirudin 1.0 mg/kg (n = 7) 0/7 2/7 5/7*
r-RGD-hirudin 0.2 mg/kg (n = 7) 2/7 2/7 3/7
r-RGD-hirudin 0.5 mg/kg (n = 7) 0/7 3/7 4/7*
r-RGD-hirudin 1.0 mg/kg (n = 7) 0/7 1/7 6/7*
Compared with NS control, r-RGD-hirudin (0.5, 1.0 mg/kg) and wt-hirudin (1.0 mg/kg) prevented thrombosis at the anastomosis vessels
signiﬁcantly (*P\0.05). However, in abciximab (0.2 mg/kg) and r-RGD-hirudin (0.2 mg/kg) treatment groups, thrombosis was obvious. The
function of the r-RGD-hirudin (0.5 mg/kg) was the same as that of the wt-hirudin (1.0 mg/kg). The antithrombotic effect of r-RGD-hirudin was
dose-dependent
Fig. 4 Pathological result. (1)
NS control group; (2) abciximab
0.2 mg/kg; (3) wt-hirudin
1.0 mg/kg; (4) r-RGD-hirudin
0.2 mg/kg; (5) r-RGD-hirudin
0.5 mg/kg; (6) r-RGD-hirudin
1.0 mg/kg: In group 1, thrombi
were observed in anastomosis
vessels; in group 2 and 4, after
3 days of anti-thrombotic
therapy, vessels were partial
patent. On the contrary, in other
3 groups, animals were treated
by wt-hirudin (1.0 mg/kg),
r-RGD-hirudin (0.5 mg/kg or
1.0 mg/kg) for 3 days, vessels
were completely patent
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123acting as an anti-thrombin agent as well as an inhibitor of
platelet aggregation. Pathological results showed that the
anti-thrombotic effect of r-RGD-hirudin was dose-depen-
dent. Its effective dose was less than the half dose of
wt-hirudin. The result of DSA showed that within 3 days of
surgery, the control group, and groups treated with abcix-
imab or a low dose of r-RGD-hirudin appeared with
thrombosis, while in the other three groups, the blood
vessels completely patent. In r-RGD-hirudin treated group,
no bleeding side-effects were observed.
However, in safety evaluation, r-RGD-hirudin (30 mg/
kg/day) was infused into six rhesus monkeys (3/sex) for 14
consecutive days; one monkey/sex was allowed to recover
without further treatment for an additional 14 days. Inter-
nal organ bleeding occurred in the treatment period, but all
side-effects disappeared in the recovery period. This result
Fig. 5 The result of DSA. Ten
minutes after operation, DSA
showed the anastomosis is
successful (Data was not
shown). (1) NS control group,
(2) abciximab 0.2 mg/kg,
(3) wt-hirudin 1.0 mg/kg,
(4) r-RGD-hirudin 0.2 mg/kg,
(5) r-RGD-hirudin 0.5 mg/kg,
(6) r-RGD-hirudin 1.0 mg/kg,
(m) Thrombus in the carotid
artery: in group1, 2 and 4,
3 days later of surgery, DSA
showed thrombus was formed in
the vessel. In group3, the vessel
was partial patent. In group 5
and 6, the vessel was
completely patent
Fig. 6 Determination of coagulation parameters before and after
treatment. r-RGD-hirudin inhibited platelet aggregation induced by
ADP and the inhibitory effect was dose-response (a); wt-hirudin does
not possess this effect. Abciximab also can inhibit platelet aggrega-
tion induced by ADP. Compared with before treatment *P\0.05,
**P\0.01; wt-hirudin (1.0 mg/kg) compared with r-RGD-hirudin
(1.0 mg/kg), (D) P\0.05. After infusion of r-RGD-hirudin or
wt-hirudin, TT (b), PT (c) and APTT (d) were prolonged signiﬁcantly.
The anti-thrombotic effect of r-RGD-hirudin was dose-dependent.
(Compared with before treatment *P\0.05, **P\0.01). Compared
with wt-hirudin (1.0 mg/kg), r-RGD-hirudin (1.0 mg/kg) inhibited
thrombin more effectively than wt-hirudin. (D) P\0.05
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123showed, after infusion of r-RGD-hirudin, bleeding was not
apparent and reversible. (Data was not shown).
Conclusion
The initial data from this pilot study demonstrate the anti-
thrombotic performance of r-RGD-hirudin. r-RGD-hirudin
may be a more effective agent for anti-coagulation and anti-
thrombosis in post-anastomosis surgery. We predicate that
r-RGD-hirudin will be able to replace heparin or wt-hirudin
and reduce the bleeding rate because of its bi-functional
action and with a much lower dosage than wt-hirudin.
Materials and methods
Materials
Enzymes and chemicals were obtained from BRL (USA) or
Sigma Chemical (USA). A multi-functional platelet-
aggregation-meter was obtained from Shanghai Sylong
Medical Apparatus and Instruments Co., Ltd.
Male rabbits (77) weighing 2.2–2.6 kg were used in the
pharmacodynamics study to evaluate safety.
Construction of r-RGD-hirudin
The r-RGD-hirudin gene was synthesized in the Key
Laboratory of Molecular Medicine at Fudan University.
The cDNA encoding r-RGD-hirudin was cloned into the
plasmid pPIC9K. The resulting expression vector was
transformed into Pichia pastoris GS115. Vector integration
into the pichia pastoris chromosome was conﬁrmed by
PCR analyses.
Expression of r-RGD-hirudin and determination of anti-
thrombin activity
Ten milliliter of BMGY (yeast extract 1%, peptone 2%,
phosphate 100 mmol/l, yeast nitrogen base 1.34%, glycerol
1%pH6.0)liquid culturemediumwasinoculatedina50 ml
conical tube with above seven colonies and incubated
overnight at 30C with vigorous shaking (250 rpm) until the
culture reached an OD600 reading of 2–3. Cells were har-
vested by centrifugation at 4,000 rpm for 10 min (4C).
Pellets were re-suspended in 10 ml of BMMY (yeast extract
1%,peptone2%,phosphate100 mmol/l,yeastnitrogenbase
1.34%, methanol 0.5% pH 6.0) and were incubated at 30C
overnight with vigorous shaking (250 rpm). Every 4 h,
samples were collected from the above BMMY culture.
Supernatantwasobtainedbycentrifugationat4,000 rpmfor
10 min, and the anti-thrombin activity was measured by
ﬁbrinogen solidiﬁcation assay [1].
Fermentation and puriﬁcation
The clone with high expression level was selected and
fermented for 2 days. The culture was centrifuged and the
supernatant was ultra-ﬁltrated, followed by gel ﬁltration
and anion exchange chromatography [10].
SDS-PAGE and LC–MS
Samples mixed with 29 buffer were subjected to 12%
reducing SDS-PAGE. The gel was stained with coomassie
brilliant blue R-250, and Pharmacia Imagemaster VDS was
used to identify the purity of products. LC–MS was used to
identify the molecular weight of r-RGD-hirudin after its
puriﬁcation.
Fibrinogen solidiﬁcation assay
Fibrinogen solidiﬁcation assay was used to measure the
anti-thrombin activity of r-RGD-hirudin [1]. Two hundred
microliter of fresh plasma was added to a 1.5 ml tube; 5 ll
of supernatant ﬂuid was added to the plasma and mixed by
vortexing. Five microliter of 100 NIH units of thrombin
were added to the above mixture and allowed to stand for
1 min: if the plasma did not clot, the supernatant had 100
anti-thrombin units. Thus, consumption of each 1 NIH unit
of thrombin is equivalent to 1 anti-thrombin unit.
Table 3 Bleeding time
0.5 h 1.0 h 1.5 h 2.0 h
NS control (n = 7) 107.7 ± 21.1 100.2 ± 13.8 103.0 ± 10.0 104.2 ± 12.0
wt-Hirudin 1.0 mg/kg (n = 7) 146.8 ± 12.5* 131.6 ± 16.6* 120.0 ± 17.9 116.9 ± 15.7
r-RGD-hirudin 0.2 mg/kg (n = 7) 106.7 ± 21.1 118.8 ± 35.3 100.0 ± 26.0 100.5 ± 17.0
r-RGD-hirudin 0.5 mg/kg (n = 7) 134.3 ± 36.2 121.0 ± 25.1 116.7 ± 28.0 102.5 ± 26.8
r-RGD-hirudin 1.0 mg/kg (n = 7) 149.5 ± 25.4* 130.8 ± 24.3* 123.2 ± 20.5 102.5 ± 14.4
Compared with NS control, bleeding time was prolonged after infusion of r-RGD-hirudin for 1.5 h (1.0 mg/kg) and wt-hirudin (1.0 mg/kg) for
1.0 h. *P\0.05
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Classic turbidity assay was used to measure the anti-platelet
aggregation activity of r-RGD-hirudin. Fresh blood was
obtained from rabbits. Sodium citrate (110 mmol/l) was
used as the anti-coagulant at a ratio of 1:9 (v/v). Platelet rich
plasma (PRP) was obtainedby centrifugation at800 rpm for
10 min,andasecondcentrifugationat3,500 rpmfor15 min
was used to prepare platelet-poor plasma (PPP). The PRP
was diluted by PPP to a platelet count of 450,000/ll. Two
hundred microliter of PRP was added in colorimetric cup,
with continuous agitation, 5 ll of wt-hirudin (control) or
puriﬁed r-RGD-hirudin was then added. The ﬁnal concen-
trations were 0.07, 0.14, 0.29, 0.57, 0.86, and 1.14 lmol/l.
Thecolorimetriccupswereincubatedat37Cfor5 min,and
ADP (20 lmol/l ﬁnal concentration) was used to induce
platelet aggregation. The percentage of aggregation was
measured for 5 min and the percentage of aggregation
inhibition was calculated by the following formula: Ii% =
(PAGmblank - PAGmCi)/PAGmblank 9 100%, where Ii%
was the inhibitory percentage, PAGmblank was maximum
platelet aggregation without wt-hirudin or r-RGD-hirudin,
and PAGmCi was maximum platelet aggregation with
wt-hirudin or r-RGD-hirudin.
Competitive inhibition assay
Competitive inhibition assay was used to determine the IC50
of the inhibitive effect of r-RGD-hirudin on platelet aggre-
gation.Flowcytometrywasusedtodeterminethebindingof
r-RGD-hirudin to the platelet [11]. Brieﬂy, in comparison
with Clopidogrel, the ﬁnal concentration was 18 mmol/l.
r-RGD-hirudin was mixed with Clopidogrel and platelets
(the plateletcount was 450,000/ll). The ﬁnal concentrations
of r-RGD-hirudin were 0.02, 0.04, 0.09, 0.18, 0.36, 0.88 and
1.78 lmol/l. ADP (20 lmol/l ﬁnal concentration) was used
to induce platelet aggregation. FITC labeled multi-clonal
anti-RGD-hirudin antibody was added and platelet was
washed by buffer (EDTA–Na2: 0.2 mmol/l, NaCl:
137 mmol/l,KCl:2.68 mmol/l,MgSO4   7H2O:0.2 mmol/l,
NaH2PO4   2H2O: 0.42 mmol/l, NaHCO3: 11.9 mmol/l,
glucose: 5.05 mmol/l) twice.
Pharmacodynamics study
Forty two male rabbits weighing 2.2–2.6 kg were used in
the study. Nembutal (40 mg/kg b.w.) was used as the
anesthetic agent. After exposing the carotid artery with
standard procedures, the artery was clamped and clipped.
The standard suture closure was then achieved using 10000
nylon suture in an interrupted fashion [12].
After operation, anti-coagulants were infused. All drugs
were administered in an intravenous bolus dose followed
by repeatedly subcutaneous injection in an equivalent dose
for 3 days (twice a day). Group 1 was infused with normal
saline as the control; group 2 was infused with abciximab
0.2 mg/kg; group 3 was infused with wt-hirudin 1.0 mg/kg;
group 4 was infused with r-RGD-hirudin 0.2 mg/kg; group
5 was infused with r-RGD-hirudin 0.5 mg/kg and group 6
was infused with r-RGD-hirudin 1.0 mg/kg [13, 14].
Digital subtraction angiography (DSA) was used for
10 min, 3 days after surgery. Vessels on the anastomosis
area were separated, and slices were prepared.
Blood samples were collected before treatment (con-
trol), 1, 24 h and 3 days after treatment. TT, PT, APTT,
and maximum platelet aggregation (PAGm) induced by
ADP were determined.
Determination of bleeding time
Thirty ﬁve male rabbits weighing 2.2–2.6 kg were used in
the study. A 0.5 cm-long wound was cut on each rabbits
auricle (avoiding damnifying the artery and vein). The
auricle was dipped in 37C NS, and simultaneously,
bleeding time was determined until bleeding stopped.
Group 1 was infused with normal saline as the control;
group 2 was infused with wt-hirudin 1.0 mg/kg; group 3
was infused with r-RGD-hirudin 0.2 mg/kg; group 4 was
infused with r-RGD-hirudin 0.5 mg/kg, and group 5 was
infused with r-RGD-hirudin 1.0 mg/kg [5]. Bleeding time
was determined at 0.5, 1.0, 1.5, and 2.0 h time points after
infusion.
Statistical analysis
Data are expressed as means ± SEM. One-way analysis of
variance (ANOVA) or Student’s t-test was used where
applicable. The differences with P-values\0.05 were
considered statistically signiﬁcant.
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